| Status: In progress | |
Indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO) who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. |
|
Medicine details |
|
| Medicine name | dupilumab (Dupixent®) |
| Formulation | 200 mg solution for injection, 300 mg solution for injection |
| Reference number | 4017 |
| Indication | As above |
| Company | Sanofi-Aventis Ltd |
| BNF chapter | Respiratory system |
| Submission type | Licence extension for paediatric use |
| Status | In progress |
| AWMSG meeting date | 14/09/2022 |
| Date of issue | TBC |
| Commercial arrangement | PAS |
| Further information |
|